This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

The Clinical Trials Industry’s Weekly News Update

Bruker buys major interest in Biognosys to boost CRO biz

Share this article

Bruker Corp has acquired a majority holding in Swiss proteomic solutions firm Biognosys AG.

The deal will add Biognosys’ proteomics, proteo-genomics, and mass spectrometry-based solutions to Bruker’s trial services unit.

In addition, according to Bruker, Biognosys’ biomarker and biopharma customers will benefit from additional services and footprint in the US.

Rohan Thakur, president of the Bruker Life-Science Mass Spectrometry division, said: “We are delighted to partner with Biognosys to expand our CRO business in the US.

“We have many common biomarker and biopharma customers, and even more potential customers may prefer a proteomics CRO services expert like Biognosys for rapid, highest quality and flexible insertion of proteomics into their biomarker or biopharma discovery and development.”

Financial terms of the investment were not disclosed. However, Bruker did state that, to facilitate the deal, several of Biognosys’ earlier investors sold their shares in a secondary transaction. The firm also said it will make new primary investments in Biognosys.

Biognosys is a spin off from the ETH Zurich University. Co-founder Ruedi Aebersold welcomed Bruker’s investment, predicting that “this new partnership between Biognosys and Bruker will further accelerate access to high performance proteomics.

“It will also provide opportunities to develop next-generation technology and methods to determine unexplored but functionally relevant dimensions of the proteome, such as the modulation of proteoform composition, and protein interaction networks as a function of cellular state.”

Proteomics demand

According to one recent study, the global market for proteomics services was worth $23.6 billion in 2021 and is projected to reach a total value of $98 billion by the end of the decade.

The authors say drug industry use of decentralize study models have increased demand for proteomics services and also suggest the coronavirus pandemic has been a growth driver.

“New trial models or strategies utilizing cutting-edge mass spectrometers for high-quality results kept gaining popularity, notably among CROs.

“For instance, in 2020, the use of cutting-edge mass spectrometer technologies enabled the discovery of proteins specific to COVID-19. These characteristics have given the proteomics sector good growth prospects.”


Share this article

Sign up for Clinical Insider email updates